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age 71 vs. 62; P<0.0001), had a higher median b2 micro-
globulin (b2M) level both at diagnosis (5.5 vs. 3.7; p¼0.0002)
and auto-HCT (4 vs. 2.5; p<0.0001), and had a higher median
serum creatinine (Cr) at auto-HCT (1.3 vs. 1.05; p¼0.05). A
higher proportion of patients in MEL 140 were older than 65
with serum Cr> 2mg/dL. Therewas no signiﬁcant difference
in disease status or high-risk cytogenetics between the 2
groups. NCI CTCv3 > grade III non-hematologic toxicity was
not signiﬁcantly different between MEL 140 and MEL 200.
TRM at 100 days and at 1 year was 0% and 0.4% in MEL 140
and 200 (p¼1.0), respectively. Complete remission (CR) rates
in MEL 140 and MEL 200 were 16% and 29%, respectively
(p¼0.03). There was no signiﬁcant difference in (CR) + very
good partial remission (VGPR), or overall response (CR +
VGPR + PR) between MEL 140 and MEL 200. Median follow
up in surviving patients in MEL 140 and 200 was 7.6 and 25
months, respectively. Fifteen (24%) and 64 (25%) patients
died in MEL 140 and MEL 200 groups, respectively, with
>90% of deaths due to recurrent disease. Median PFS was
26.4 and 30.6 months in MEL 140 and MEL 200 groups,
respectively (p¼0.46). Median OS was 38.4 and 93.0 months
in MEL 140 and MEL 200 groups, respectively (p¼0.02).
However, there was no signiﬁcant difference in median PFS
(26 vs. 24.4 months) or median OS (38.6 vs. 62.2 months) in
patients older than 65 between MEL 140 and MEL 200.
Similarly, there was no signiﬁcant difference in median PFS
(24.5 vs. 31.3 months) or median OS (32.1 months vs. 69.3
months) in patients with a serum Cr > 2 mg/d between MEL
140 and MEL 200.
Conclusion: The dose of melphalan can be safely reduced to
140 mg/m2 in patients >65 or with renal insufﬁciency
without adversely impacting the overall response rate or PFS.460
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Background: Rituximab and inﬂiximab are two monoclonal
antibodies administered intravenously. Both medications are
generally administered over prolonged infusion times per
manufacturer guidelines in order to avoid infusion-related
toxicities. Rituximab is a chimeric anti-CD20 monoclonal
antibody used primarily for the treatment of EBV viremia,
autoimmune cytopenias and steroid refractory graft versus
host disease (srGVHD) in hematopoietic stem cell transplant
patients (HSCT) at Cincinnati Children’s Hospital Medical
Center (CCHMC). Recommended infusion times for ritux-
imab average 5-6 hours for the initial dose and 3-4 hours for
subsequent doses. Inﬂiximab is an anti-TNFa monoclonal
antibody used for srGVHD in HSCT patients at CCHMC. Rec-
ommended infusion of inﬂiximab is over 2-3 hours. Due to
the these infusion times, administration of both medications
is associated with decreased patient satisfaction, increased
health care costs and can also lead to compatibility/access
issues. Data exists to support rapid infusion (RI) adminis-
tration (over 1 hour) of these agents in non-HSCT adult pa-
tients, but data in pediatric HSCT patients is limited. Here wedescribe our experience with 1-hour infusions of rituximab
and inﬂiximab at CCHMC.
Methods: All HSCT patients who received rituximab or
inﬂiximab between March 2013 and October 2013 were
administered their ﬁrst dose by the standard manufacturer
guidelines. If patients tolerated the ﬁrst infusion they were
eligible to receive infusion of subsequent doses over 1 hour.
Patients were observed for infusion related reactions during
and for 30 minutes after infusion. Additionally, patients and
family members were advised to report any possible re-
actions within the 24 hours following infusion.
Results: Seven patients received 24 RI rituximab doses. The
median number of doses per patient was 3; (range 1-7). Five
patients were on corticosteroids as part of their baseline
regimen, no patients (including those not on baseline ste-
roids) received additional steroid pre-medication prior to
infusion. No adverse effects were reported with the RI of
rituximab. A total of 49 doses of RI inﬂiximab were admin-
istered to 8 patients. All 8 patients were on corticosteroids as
part of their daily regimen and no one received additional
steroid as pre-medication prior to their infusion. The median
number of inﬂiximab RIs per patient was 7.5 (range 1-17
doses). One patient receiving RI inﬂiximab experienced a
rash that resolved without intervention during the ﬁrst RI.
The patient received 4 additional RIs without side effects. No
additional side effects were seen in any other patients.
Conclusion: Rapid-infusions of rituximab and inﬂiximab
were safe and well tolerated when administered as the sec-
ond and subsequent infusion in a course of therapy. Patient
and family satisfaction were also improved.461
Safety and Efﬁcacy of Plerixafor for Mobilization of
Peripheral Blood Stem Cells in Pediatric Patients
Ashley Teusink 1, Sue L. Pinkard 2, Stella M. Davies 3,
Mark Mueller 4, Sonata Jodele 3. 1 Division of Pharmacy,
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH;
2Hoxworth Blood Center, University of Cincinnati, Cincinnati,
OH; 3 Bone Marrow Transplantation and Immune Deﬁciency,
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH;
4 Cancer and Blood Diseases Institute Blood and Marrow
Transplant, Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH
Background: Chemotherapy followed by ﬁlgrastim is the
most common strategy used to mobilize cells for high dose
chemotherapy and autologous stem cell transplantation.
Unfortunately, this method does not always lead to adequate
cell collection in heavily pretreated patients with relapsed
malignancies or if multiple transplants are required. Plerix-
afor is an agent that has been studied in adults and has been
shown to be safe and efﬁcacious in the mobilization of pe-
ripheral blood stem cells (PBSC). Plerixafor is hematopoietic
stem cell mobilizer which inhibits the CXCR4 chemokine
receptor and blocks binding of its cognate ligand, stromal
cell-derived factor-1-alpha (SDF-1-alpha) which results in
leukocytosis and elevations in circulating hematopoietic
progenitor cells. Despite its use in adults, little evidence ex-
ists to support its use in children. Here we report our ob-
servations of 11 children at Cincinnati Children’s Hospital
Medical Center (CCHMC) who received plerixafor tomobilize
PBSC.
Table 1
Cytoreductive
Response n (%)
No Cytoreductive
Response n (%)
n¼16 8 (50) 8 (50)
Alive at Day 100 5 (31) 6 (38)
Alive, Day 100 Not Reached 1 (25) 1 (25)
Alive, in remission 5 (31) 3 (19)
Alive, relapsed 0 (0) 1 (6)
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plerixafor as part of their mobilization regimen at CCHMC
between January 2011 and September 2013 was conducted.
All patients receiving at least one dose were included. Data
on the number of plerixafor doses administered, cells
collected, and adverse events related to plerixafor were
collected.
Results: Eleven patients received plerixafor during the
designated time period; 9/11 patients (81.8%) had relapsed
malignancies and 2/11 patients (18.2%) required 3 and 4
autologous stem cell transplants for brain tumors. The me-
dian age of patients receiving plerixafor was 6 years (range 3-
15 years). All patients were given 0.24 mg/kg of plerixafor
and the median number of plerixafor doses received was 3
(range 1-4 doses). Collection target was 1x106 of CD34+cells/
kg for each transplant. An adequate number of CD34+ cells
were obtained in 9 of 11 patients (81.8%). The median
number of CD34+ cells collected for patients who reached
collection goal was 5.7x 106/kg (range 1.3-12.4 x 106/kg). No
acute adverse events were noted to be attributable to pler-
ixafor administration.
Conclusion: Our ﬁndings suggest that plerixafor use in
children is safe and efﬁcacious for the mobilization of PBSCs
in children with relapsed malignancies or requiring stem
cells for multiple transplants.462
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Outcomes in patients with relapsed/refractory acute myeloid
leukemia or advancedmyelodysplastic syndromewith active
disease at the time of allogeneic hematopoietic stem cell
transplant (HSCT) are generally poor. Published data indicate
the purine analog clofarabine can be used for cytoreduction
in patients with active disease as a “bridge” to HSCT when
followed by a standard conditioning regimen.
At Weill Cornell Medical Center (WC) clofarabine has been
used in refractory patients as a bridge to HSCT since 2011.
While published studies transplanted patients at cytopenic
nadir following clofarabine therapy, WC transplanted pa-
tients without regard to cytoreductive response.
The purpose of this study was to retrospectively examine
survival following clofarabine therapy and to determine if
cytoreduction affects outcomes. Secondaryoutcomes included
cytoreduction (deﬁned as post-treatment cellularity<20% and
blasts <10%), relapse after transplant, and non-hematologic
toxicity.
The study included adult patients who received clofarabine
30 mg/m2/day IV x 5 days prior to HSCT between November
2011 and June 2013. Twenty-one patients received a clofar-
abine bridge; 18 (86%) proceeded to HCST. The three who did
not were septic at the scheduled time of transplant. Two
patients refused a day 14 bone marrow and were not eval-
uated for response. Both died post-transplant.
Of the evaluable 16 patients, 8 (50%) are alive and in remis-
sion at a median of 3 months (range 2-10). One is alive, but
relapsed. Overall, 5 patients (31%) relapsed. Of the 7 patients
who died after transplant, median overall survival was 94days (range 5-188). Causes of death included relapse, sepsis,
and engraftment failure.
Eight (50%) patients achieved the pre-deﬁned cytoreductive
response. Five are alive and in remission at a median of
5 months (range 3-10). See table 1.
Based on preliminary analysis, cytoreduction with a clofar-
abine bridge appears to positively affect outcomes of re-
fractory patients who proceed to HSCT.463
Inﬂuence of Antifungal Prophylaxis on
Cyclophosphosphamide Based Regimen Transplant
Outcomes
Devona Williams 1, Gabrielle Flash 2. 1 Children’s National
Health System, Washington, DC; 2 Pharmacy, Childrens
National Health System, washington, DC
Cyclophosphamide is a chemotherapeutic agent that may be
included in stem cell transplant preparative regimens.
Cyclophosphamide is a pro-drug that is converted to cyto-
toxic metabolites via multiple pathways of the cytochrome
P-450 enzyme system. The triazole antifungal agents may be
prescribed as fungal prophylaxis for stem cell transplant
patients. The triazole antifungals are inhibitors of some cy-
tochrome P-450 pathways that are utilized for cyclophos-
phamide conversion. Due to this drug interaction, some
transplant centers will substitute an alternate agent instead
of a triazole antifungal during cyclophosphamide therapy.
Adult data has demonstrated that there is no difference in
the AUC of the phosphoramide metabolite when given with
ﬂuconazole. The goal of this review is to examine if anti-
fungal drug interactions inﬂuence stem cell transplant sur-
vival or disease relapse. This is a single center, retrospective
review of 5 years of transplant outcomes for pediatric and
young adult patients diagnosed with a hematologic malig-
nancy that underwent hematopoietic stem cell transplant
and received cyclophosphamide as part of the transplant
preparative regimen. Outcomes measured were survival,
relapse or progressive disease and non-relapse mortality.
The medical charts of 25 patients with diagnoses of AML,
ALL, MDS and Lymphoma were reviewed. Outcomes were
stratiﬁed for voriconazole, ﬂuconazole and non-azole anti-
fungal patients. Survival results were 50% for voriconazole,
64% for ﬂuconazole and 33% for non-azole therapies. Relapse
or progressive disease rates were 16% for voriconazole, 18%
for ﬂuconazole and 33% for non-azole therapies. Non-relapse
mortality was 33% for voriconazole, 18% for ﬂuconazole and
33% for non-azole therapies. For azole versus non-azole
therapy relapse rates were 17% versus 33% respectively. In a
small cohort of pediatric and young adult patients, the
cytochrome P-450 interaction of azole antifungals and
cyclophosphamide does not appear to inﬂuence transplant
